Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?
Status:
Terminated
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Th mechanism of action of dapagliflozin is via sodium-glucose co-transporter 2 (SGLT2)
inhibition. Sodium-glucose co-transporter 2 inhibition is associated with moderate weight
(fat) loss, in addition to other health benefits, including decreased blood pressure,
decreased inflammation, and decreased oxidative stress. It is unclear as to whether these
health benefits are due to SGLT2 inhibition per se, or as a secondary effect of weight loss.